Search Results - "Kramers, Bart J"

Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan by Kramers, Bart J., van Gastel, Maatje D.A., Boertien, Wendy E., Meijer, Esther, Gansevoort, Ron T.

“…The vasopressin V2 receptor antagonist (V2RA) tolvaptan is the first drug that has been shown to slow the rate of kidney function decline in patients with…”
Get full text

Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors by Eickhoff, Mie K, Dekkers, Claire C J, Kramers, Bart J, Laverman, Gozewijn Dirk, Frimodt-Møller, Marie, Jørgensen, Niklas Rye, Faber, Jens, Danser, A H Jan, Gansevoort, Ron T, Rossing, Peter, Persson, Frederik, Heerspink, Hiddo J L

“…Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart and kidney failure in patients with type 2 diabetes, possibly due to diuretic…”
Get full text

Effects of Treating Primary Aldosteronism on Renal Function by Kramers, Bart J., Kramers, Cornelis, Lenders, Jacques W. M., Deinum, Jaap

“…Longstanding primary aldosteronism (PA) has deleterious effects on renal function, often masked until treatment (adrenalectomy or spironolactone) is initiated…”
Get full text

HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial by Bais, Thomas, Meijer, Esther, Kramers, Bart J, Vart, Priya, Vervloet, Marc, Salih, Mahdi, Bammens, Bert, Demoulin, Nathalie, Todorova, Polina, Müller, Roman-Ulrich, Halbritter, Jan, Paliege, Alexander, Gall, Emilie Cornec-Le, Knebelmann, Bertrand, Torra, Roser, Ong, Albert C M, Karet Frankl, Fiona E, Gansevoort, Ron T

“…Autosomal dominant polycystic kidney disease (ADPKD) leads to progressive renal cyst formation and loss of kidney function in most patients. Vasopressin 2…”
Get full text

Case report: a thiazide diuretic to treat polyuria induced by tolvaptan by Kramers, Bart J, van Gastel, Maatje D A, Meijer, Esther, Gansevoort, Ron T

“…Currently, the vasopressin V2 receptor antagonist tolvaptan is the only available treatment for autosomal dominant polycystic kidney disease (ADPKD), but there…”
Get full text

Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients by Geertsema, Paul, Koorevaar, Iris W, Ipema, Karin J R, Kramers, Bart J, Casteleijn, Niek F, Gansevoort, Ron T, Meijer, Esther

“…ABSTRACT Background The only treatment proven to be renoprotective in autosomal dominant polycystic kidney disease (ADPKD) is a vasopressin V2-receptor…”
Get full text

Prostaglandin E2, osmoregulation and disease progression in autosomal dominant polycystic kidney disease by Geurts, Frank, Xue, Laixi, Kramers, Bart J, Zietse, Robert, Gansevoort, Ron T, Fenton, Robert A, Meijer, Esther, Salih, Mahdi, Hoorn, Ewout J

“…Prostaglandin E2 (PGE2) plays a physiological role in osmoregulation, a process that is affected early in autosomal dominant polycystic kidney disease (ADPKD)…”
Get full text

Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial by Kramers, Bart J, Koorevaar, Iris W, van Gastel, Maatje D A, van Goor, Harry, Hallows, Kenneth R, Heerspink, Hiddo L, Li, Hui, Leonhard, Wouter N, Peters, Dorien J M, Qiu, Jiedong, Touw, Daan J, Gansevoort, Ron T, Meijer, Esther

“…The vasopressin V2 receptor antagonist tolvaptan is the only drug that has been proven to be nephroprotective in autosomal dominant polycystic kidney disease…”
Get full text

Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study by Kramers, Bart J, Koorevaar, Iris W, De Boer, Rudolf, Hoorn, Ewout J, Pena, Michelle J, Gansevoort, Ron T, Meijer, Esther

“…Abstract Background In autosomal dominant polycystic kidney disease (ADPKD), hypertension is prevalent and cardiovascular events are the main cause of death…”
Get full text

The association of glucagon with disease severity and progression in patients with autosomal dominant polycystic kidney disease: an observational cohort study by Knol, Martine G E, Kramers, Bart J, Gansevoort, Ron T, van Gastel, Maatje D A

“…ABSTRACT Background Mammalian target of rapamycin (mTOR) inhibitors and ketogenesis have been shown to ameliorate disease progression in experimental autosomal…”
Get full text

Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD by Messchendorp, A Lianne, Kramers, Bart J, Spithoven, Edwin M, Stade, Katrin, Meijer, Esther, Gansevoort, Ron T

Get full text

Effects of Salt and Protein Intake on Polyuria in Tolvaptan-Treated ADPKD Patients: A Randomized Controlled Trial: TH-PO424 by Geertsema, Paul, Koorevaar, Iris W., Ipema, Karin, Kramers, Bart J., Casteleijn, Niek F., Gansevoort, Ron T., Meijer, Esther

Get full text

SaO003USE OF THIAZIDE DIURETICS DOES NOT WORSEN DISEASE PROGRESSION IN ADPKD by Kramers, Bart J, Gansevoort, Ron T, De Boer, Rudolf, Drenth, Joost P h, De Fijter, Johan W, Wetzels, Jack F M, Zietse, Robert, Meijer, Esther

Get full text